- Home
- GDYN vs NRIX Comparison
GDYN vs NRIX Comparison
Compare GDYN & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDYN
- NRIX
- Stock Information
- Founded
- GDYN 2006
- NRIX 2009
- Country
- GDYN United States
- NRIX United States
- Employees
- GDYN N/A
- NRIX N/A
- Industry
- GDYN Computer Software: Prepackaged Software
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- GDYN Technology
- NRIX Health Care
- Exchange
- GDYN Nasdaq
- NRIX Nasdaq
- Market Cap
- GDYN 648.6M
- NRIX 750.4M
- IPO Year
- GDYN N/A
- NRIX 2020
- Fundamental
- Price
- GDYN $8.10
- NRIX $11.90
- Analyst Decision
- GDYN Strong Buy
- NRIX Strong Buy
- Analyst Count
- GDYN 4
- NRIX 14
- Target Price
- GDYN $14.00
- NRIX $26.29
- AVG Volume (30 Days)
- GDYN 1.0M
- NRIX 1.7M
- Earning Date
- GDYN 10-30-2025
- NRIX 10-09-2025
- Dividend Yield
- GDYN N/A
- NRIX N/A
- EPS Growth
- GDYN N/A
- NRIX N/A
- EPS
- GDYN 0.19
- NRIX N/A
- Revenue
- GDYN $389,227,000.00
- NRIX $83,687,000.00
- Revenue This Year
- GDYN $20.79
- NRIX $58.48
- Revenue Next Year
- GDYN $10.71
- NRIX N/A
- P/E Ratio
- GDYN $42.10
- NRIX N/A
- Revenue Growth
- GDYN 22.27
- NRIX 48.32
- 52 Week Low
- GDYN $7.37
- NRIX $8.18
- 52 Week High
- GDYN $25.50
- NRIX $29.56
- Technical
- Relative Strength Index (RSI)
- GDYN 51.60
- NRIX 64.49
- Support Level
- GDYN $7.97
- NRIX $11.37
- Resistance Level
- GDYN $8.46
- NRIX $12.45
- Average True Range (ATR)
- GDYN 0.30
- NRIX 0.75
- MACD
- GDYN 0.04
- NRIX 0.20
- Stochastic Oscillator
- GDYN 66.02
- NRIX 84.06
About GDYN Grid Dynamics Holdings Inc.
Grid Dynamics Holdings Inc is a provider of technology consulting, platform and product engineering, and advanced analytics services. The company delivers tailored solutions in several industry verticals like Tech, Media and Telecom, Retail, Finance and Consumer Packaged goods (CPG)/manufacturing. The company derives maximum revenue from Retails. Geographically company earns revenue from North America, Europe and other regions.
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.